Objectives: To examine the impact of intracavernosal therapy on libido, ejaculatory control, quality of life and treatment dependency in men with erectile failure. Furthermore to assess the drop-out rate and reasons for dissatisfaction with the technique. Subjects and methods: Questionnaires were sent to 1116 subjects with erectile failure who had previously elected to use intracavernosal therapy in the period 1995 ± 1997. Results: The response rate was 72.5%. The majority of erections lasted 30 ± 60 min, 10 ± 20% of the erections were considered unsatisfactory for intercourse and 15% of subjects reported erections lasting longer than 5 h on at least 10% of the occasions. Bleeding at the injection site occurred in 60% on at least 10% of the occasions and various degrees of deformation of the penis shaft were reported by 10%. The latter was related to the age of the subject and not the type of medication employed. Forty percent experienced at least partially improved control over ejaculation and almost 50% experienced some degree of increase in libido. One quarter retained penile rigidity after ejaculation but this was age-dependent. In those satis®ed with intracavernosal treatment, 80% admitted that it had improved the quality of their lives. Sixty percent did not feel that their dependency on intracavernosal treatment had lessened during the treatment period.
Introduction
Intracavernosal injection is a well-documented and an effective means of treating erectile failure which has been available for over a decade. 1 ± 3 Various follow-up studies have provided information regarding the long term use of IC treatment and how subjects have adapted to the technique, 4 ± 6 but invariably, their ®ndings have been based on relatively few subjects. This has made it dif®cult to assess, in particular, the impact of age on patient satisfaction and the extent of side-effects. In addition, few reports have focused on the degree to which the mode of injection or type of medication in¯uence the reaction to this form of treatment. To provide this additional information, a questionnaire was sent to over a thousand subjects who had previously embarked on IC treatment. The questions were designed to assess the use, satisfaction, ef®cacy, dependency and reaction to this form of therapy and the extent and reasons for drop-out.
Materials and methods

Study group
The men recruited for this study were 23 ± 93 y old and had attended our andrology clinic between 1995 and 1997 because of various degrees of erectile failure. They were from all parts of Norway, both rural and urban areas. All had been examined by one of two of the same physicians. The examination involved hormone determinations, penile plethysmography, transrectal ultrasound, simpli®ed neurological tests and testing with cavernosal medication, including increasing doses of prostaglandin E1 (PGE, 10 ± 20mg), papaverine-phentolamine (15 mg; 0.5 mg) and Trimix (10 mg PGE; 15 mg papaverine; 0.5 mg phentolamine). Based on this examination, the presumptive major cause of the erectile failure could be roughly de®ned. Figure 1 summarizes the different etiological categories of those responding to the questionnaire. In Norway in this period, men with erectile failure had the following choices of treatment modalities: psychotherapy, vacuum pump, venous ligation (after dynamic cavernosography), arterial by-pass (in selected men under 65 y of age), oral medication (yohimbine), hormonal treatment and intracavernosal medication. Only those electing to use intracavernosal treatment and provided with a prescription for intracavernosal medication were included in the study. In addition to the conventional disposable 1 ml insulin syringe with ®xed needle, subjects were also given the choice of various auto-injectors including Injectease or B ± D injector (Becton Dickinson, USA), a semi-automatic device involving automatic needle insertion but with manual drug delivery, Autoinjector (Owen Mumford Ltd, Oxford, UK) a fully automatic needle insertor and drug injector and the D-penn (Disetronic, Switzerland) which is a manual injection device with a reservoir of the drug (usually PGE) enabling multiple injections without the need for re®ll.
Questionnaire
Subjects were selected consecutively from the data base and sent a questionnaire with a stamp addressed envelope. To guarantee anonymity, each was given a code number to which only one of the investigators was privy. Twenty eight questions were asked which were in the majority of cases multiple choice. In some cases, the subject was asked to elaborate with further details. The answers were then coded by an independent investigator and analysed by a statistical programme (Instat, GraphPad Software, San Diego California).
RESULTS
Response to questionnaire
One thousand, one hundred and sixteen consecutive patients were sent questionnaires. Of these, 13 were returned because the subject had died and 47 because of change to an unknown address, reducing the number of potential recruits to 1056. In spite of reminders, 216 did not reply and 52 sent blank questionnaires indicating that they did not want to participate in the study. This corresponded to a response rate of 74.6%. Of these, 22 replied that they had changed their minds after the initial consultation and had never embarked on IC therapy. Information was thus derived from 766 individuals, an overall response rate of 72.5%. Figure 2 shows the age distribution of the 766 responders and 216 non-responders to the questionnaire. The average ages were 57 and 55 y Figure 1 Presumptive main etiologies of erectile failure in 766 men responding to a questionnaire on intracavernosal treatment. The ideopathic group contains those whose etiology could not be clearly de®ned, for example, both vascular and psychogenic components.
Characteristics of the subjects
Intracavernosal therapy for erectile failure K Purvis et al respectively with a tendency for younger subjects not to reply to the questionnaire. Foreign nationals constituted 7 and 8.3% of the non-responders and responders, respectively. Over one third (35.3%) were current smokers and approximately half (45.9%) were using some form of chronic medication. Table 1 indicates that in the majority of cases this involved anti-hypertensive drugs. Under one ®fth used diabetic medication. Approximately 60%(61.4) were currently using IC therapy in the majority of cases (79%) for longer than six months.
Use of ICI treatment
Less than half of the subjects used IC therapy 2 ± 3 times a month (23.1%, 44.2%, 21.9%, 8.4% and 2.4% used IC treatment once or less, 2 ± 3, 4 ± 6, 7 ± 10 and b 10 times a month respectively; 90.1% responded to the question). The frequency of use was age-related ( Figure 3) , the older the subject the less frequently he employed the technique.
Mode of treatment
Within the total study group, 34.7% used low dose PGE (`10 mg), 9.7% used high dose PGE (10 ± 20 mg) Figure 2 Age distribution of responders and non responders to a questionnaire on the intracavernosal treatment of erectile failure. 
Response to IC therapy
The duration of response. The majority of subjects had an erection which lasted 30 ± 60 min (18.9%, 19.8%, 30%, 19.1% and 12.2% reported erections lasting less than 15 min, 15 ± 30 min, 30 ± 60 min, 60 ± 120 min and longer than 120 min respectively; 85.6% responded). In 85% of the cases, none of these erections exceeded 5 h whereas 2% regularly experienced erections lasting longer than 5 h ( Table 2 ). In those subjects recording no priapism, 55% used`10 mg PGE (D-penn or other forms of injection), 22% 10 ± 20 mg PGE, 4% TRIMIX and 18% papaverineaphentolamine. The corresponding values for subjects recording an erection exceeding 5 h on at least 40% of the occasions were 58%, 25%, 0% and 16% respectively. Therefore, no relationship could be demonstrated between the type of medication used and the tendency towards prolonged erections.
The quality of the response. In reply to the question concerning how often the erections induced by IC therapy were unsatisfactory, the majority (59.1%) replied that this occurred on between 10 ± 20% of the occasions (36.9%, 22.2%, 12.3%, 4.9%, 7% and 16.7% reported unsatisfactory erections on 10, 20, 30, 40, 50 and over 50% of occasions respectively; 79.9% responded). The proportion of unsatisfactory erections did not appear to be related to the age of the subject (not shown).
Effects of ejaculation.
Approximately one third (32.1%) reported losing their erections after ejaculation whereas one quarter (24.3%) maintained rigidity and over 43 .5% recorded only a partial loss of rigidity after ejaculation. This response appeared to be age-related and indicated that twice as many men in the over-seventies age group as those less than forty, lost rigidity after ejaculation ( Table 3 ). The type of IC medication did not appear to determine whether rigidity was lost or sustained after ejaculation (data not shown).
In Table 2) .
Approximately one ®fth (19.2%) recorded alterations in penis size andaor shape after IC therapy (91.6% answered the question), whilst 16.5% were uncertain. When asked to specify these changes the following replies were noted: various degrees of bending of the penile shaft: 57.1%; relative reduction in the volume of the glans: 19%; an increase in the lengthathickness of the penis: 23.8%. Therefore, over 10% of all subjects using IC therapy reported some form of penile contortion during erection.
Impact of IC therapy on libido and quality of life. Over forty percent (42.2%) of those responding to the question (94.2%) replied that their desire for sex was not in¯uenced by erection treatment, one quarter replied in the af®rmative (23.1%); 23.3% admitted to a partial effect on libido, whilst 11.4% were uncertain. In those satis®ed with IC therapy, the corresponding values were 30, 59.6, 21.2 and 8.4% respectively. Therefore, almost 60% of those who were satis®ed with IC treatment report an increase in sexual desire. Intracavernosal therapy for erectile failure K Purvis et al
Similarly, when those who had reported satisfaction with IC therapy were asked whether this had had a positive effect on the quality of their lives (89% responded), almost 80% (78.8%) reported in the af®rmative. The remaining replies were no: 3.4%, partially 14.9%; uncertain 2.7%. In those dissatis®ed or partially satis®ed with IC therapy, the corresponding values were 9, 65.9, 15.9 and 9.1% and 34.1, 16.6, 40.6 and 8.8% respectively.
Effects on spontaneous erections and dependency on IC therapy. Whereas 36.7% had lost all spontaneous erections before beginning IC therapy, over half (56.3%) still experienced some natural erections (94.9% responded). Seven percent could not remember. IC therapy did not improve these spontaneous erections in approximately half (49.3%). In contrast, 17.8% and 21.6% recorded a de®nite or partial improvement, respectively. Eleven percent were uncertain (88.6% responded).
The majority (59.3%) did not feel that their dependence on IC therapy had changed during treatment. Only 16.6% felt less of a dependency and 24.1% were uncertain (88.8% responded). When asked whether they could reduce the dose necessary for adequate rigidity as treatment progressed, the answers were as follows: yes: 14.4%; no: 55%; uncertain: 30.6% (89.9% responded).
Current users of IC treatment and drop-outs
Approximately 60% (61.4%) were currently using IC therapy, 38.6% had dropped out after varying periods. Over one third (37.4%) had dropped out within the ®rst two months, 21.2, 20.1 and 20.8% stopped treatment after 3 ± 4, 5 ± 6 and more than 6 months, respectively. The majority (79%) of those currently using IC therapy had done so for over six months (®gure 4). Mode of injection. Those men discontinuing with IC therapy were more likely to have used manual injection with the D-penn (35.3% compared to 27.7% continuing) and less likely to have used the semi-automatic BD pistol (13.1% compared to 23.7% continuing). Use of the simple disposable 1 ml syringe or the fully automatic RFSU pistol did not appear to in¯uence the decision to use the treatment (approximately 25% continuing and discontinuing for both modes of injection).
Type of IC medication. The only IC medication which appeared to in¯uence acceptance of IC therapy was papaverineaphentolamine. The numbers of subjects currently using IC therapy used this medication almost twice as much as those dropping out of the programme (24.3% and 14.6%, respectively). The other data were as follows: current users: 33.1%. 10.3%, 3.6% and 27% used low dose PGE (0 ± 10 mg), high dose PGE (0 ± 20 mg), TRIMIX and D-penn PGE, respectively; drop-outs: 36.2%, 9.0%, 3.7% and 36.5% for the same medications, respectively.
Satisfaction with IC therapy
94.3% answered the question. Of those currently using IC therapy, over half (55.6%) were satis®ed, 31.8% were partly satis®ed, 10.8% were dissatis®ed with the treatment and 1.7% were uncertain. Of those who had discontinued with the treatment, almost one ®fth had been satis®ed, 31.8% had been partly satis®ed and 41.6% had been dissatis®ed with this form of therapy (7.5% were uncertain).
In¯uence of age on level of satisfaction. In those currently using IC therapy a greater degree of dissatisfaction was associated with the younger age groups (®gure 5). Almost one ®fth of those 25 ± 40 y old registered dissatisfaction with the technique compared to less than one tenth in the oldest group.
In¯uence of the mode of injection. Table 4 indicates that fewer men who were dissatis®ed with IC treatment used the semi-automatic BD pistol than those recording satisfaction. Use of the manual Intracavernosal therapy for erectile failure K Purvis et al syringe or fully automatic injector did not appear to in¯uence the level of satisfaction.
Impact of smoking. Thirty nine percent of non smokers dropped out of the IC programme compared to 36% of smokers. Over one ®fth of non smokers (21%) registered dissatisfaction with IC treatment because of inadequate rigidity. Only 15% of smokers were dissatis®ed for the same reason. Table 5 summarises the reasons why subjects expressed dissatisfaction with IC therapy or had dropped out of the treatment programme. The major reason, which was recorded by almost one ®fth, was inadequate penile rigidity. Other important reasons were that the product was too expensive, that the treatment was associated with too much discomfort or pain and that the procedure necessitated a lack of spontaneity in the initiation of intercourse.
Reasons of dissatisfaction with IC therapy
Some of the reasons for dissatisfaction andaor dropping out of IC treatment were age-related. The return of spontaneous erections as a reason for dropping out of the treatment was more associated with the younger age group and rarely registered in the group over 70 y of age (Table 6 ). Similarly dissatisfaction because of inadequate rigidity was far less recorded in the younger group and gradually increased with age. Pain or discomfort associated with the injection was recorded three times more often in the 25 ± 40 y olds than those over 71 y of age and dissatisfaction because of negative alterations in penis shape generally increased as the subject aged. The risk of developing penile deformity was four times greater in the 71 ± 93 y age group than those under 41 y. Other reasons for dissatisfaction such as needle phobia, anxiety for side-effects, concerns about the price and that the technique was too complicated could not be related to age.
Attitudes of the partner to IC treatment 89.4% answered the questions regarding the partners reaction to IC treatment. Over 40% (40.3%) registered partner satisfaction with the technique, 26.3% that their partners were partly satis®ed, Figure 5 Relationship between age and dissatisfaction with intracavernosal (IC) treatment in current users. The values represent percentages within each group answering in the af®rmative to the question.
Intracavernosal therapy for erectile failure K Purvis et al 16.4% partner dissatisfaction and 17.1% were uncertain. The reasons for their dissatisfaction are summarised in Table 7 . Almost one third expressed dissatisfaction with the extent of penile rigidity whilst another third emphasised the lack of spontaneity which the technique involved. Two other major reasons related to the price of the procedure and that it was too complicated.
Discussion
The response to the questionnaire was satisfactory in view of its relatively complexity and the large number of questions asked. In con®rmation of a previous report, 7 a relatively large number of subjects were currently smokers and almost half were using some form of chronic medication, in particular, antihypertensive or diabetic medication. All three factors have been implicated in the etiology of organic impotence. 8 ± 11 In those subjects currently using IC treatment for their erection dif®culties, the majority used the technique 1 ± 3 times a month but this was clearly age-related, in keeping with the acknowledged age-differences in the frequency of intercourse in the general population. 12 ± 14 Varying concentrations of prostaglandin were the most commonly employed medication, used by 75% of the group. This re¯ects the general treatment strategy of our clinic which involves an initial testing with PGE followed by papaverineaphentolamine and TRIMIX if the response is not satisfactory andaor the erections are painful. The large numbers using automatic injection devices (40%) or D-penn (32%) also re¯ects the policy of the clinic and the opinion that such devices would reduce the numbers dropping out of the treatment programme. After consultation, all subjects had been encouraged to titrate the dose of medication until they had reached a satisfactory duration of erection. The questionnaire indicated that one third obtained an erection which lasted 30 ± 60 min, and an additional third experienced a response greater than 60 min. However, this does not necessarily re¯ect personal choice. Although the duration of sexual activity is invariably shorter, many subjects had experienced that doses of medication giving shorter durations of erection often resulted in poorer rigidity. A relatively large number (15%) experienced erections on at least some occasions which exceeded 5 h, 2% on half of the occasions. This could not be related to the type of medication used. Although none of these subjects had to enlist medical help for their relative priapism, it indicates that those electing to use IC therapy should be contacted after a period of use to control whether the technique is being used properly or whether the response to the medication has changed.
A large number (80%) admitted that not all erections induced by IC therapy were satisfactory for intercourse, although the majority admitted that this occurred on only 10 ± 20% of the occasions. This variability in the reaction to IC treatment may re¯ect several factors: the threshold of the response, the dose of medication used, variation in the technique and the varying impact of various lifestyle factors such as stress, general anxiety and the responsiveness of the partner. Those using relatively low doses of medication closer to the threshold of the response would be expected to be more susceptible to such factors as stress. Interestingly, there was no indication that the frequency of unsatisfactory erections after IC treatment increased with age, implying that the lack of response was more related to the technique or lifestyle than organic factors.
Over 40% reported that IC medication either partly or convincingly gave them more control over their ejaculation. Moreover, almost 70% admitted that once ejaculation had occurred they were able to completely or partially maintain their erection. These advantages of this form of treatment have been utilised in the treatment of premature ejaculation. 15 However, the effect appears to be age-related, older men losing their erections after ejaculation much more often than younger age-groups. This tendency is also seen in the normal, potent population 16 , and presumably re¯ects age-related changes in neural or cavernosal function.
Two relatively frequent complications of IC treatment were bleeding at the injection site and alterations in penis shape. Two thirds of the study group admitted experiencing bleedings on at least 10% of the occasions. In a multi-centre study involving 683 men after six months of self injection, only 8% reported ecchymosis or hematomas. 4 In contrast Lakin et al 17 reported small hematomas in 21% of 100 patients after 29 months. The reason for the higher incidence of site bleedings in the present study is unclear. It may re¯ect the length of the observation period, the frequency of injection, the needle gauge or simply differences in the patients opinion of what constitutes a bleeding. In our own study, all forms of bleedings were asked to be noted by the patient including the slight bleeding observed Intracavernosal therapy for erectile failure K Purvis et al at the puncture site after removal of the needle. All subjects had received training instructions during the consultations and advised not to inject in the tumescent organ to avoid hemorrages associated with raised intracavernosal pressure. More interesting is the ®ndings that approximately 10% of the subjects reported the development of abnormal deviation of the penile shaft with IC injection, which could not be related to the type of medication used. The latter observation is particularly relevant since papaverineaphentolamine has been implicated in the development of ®brous changes in the cavernosal tissue with long term use in up to 57% of subjects. 17 ± 21 Although these ®brous changes were initially reported to be much more infrequent after PGE therapy, approximately 2% or less 4, 22, 23 or non-existent, 24 ,25 a growing number of researchers are reporting contradictory ®ndings. Thus Porst 26 reported indurations in 11.5% of his patients using intracavernosal PGE and Chen 27 reported 15% in 68 subjects. More recently, Chew 28 reported that 23.3% of 245 subjects developed penile ®brosis using an average of 13 mg PGE per injection ®ve times a month for 29 months. Factors which increased the risk of developing ®brosis included the age of the subject and the total amount of PGE and total number of injections administered. It must be emphasised that in the majority of studies, penile ®brosis was evaluated by the physician either by direct examination or external ultrasound. In the study by Chew 28 only 5% of the total study group reported penile curvature compared to 10% in this present study. It is likely that these marked alterations in penile form, which are independent of the medication used, re¯ect a general disposition of a group of subjects to the development of Peyronie-like changes in the penis. Peyronie's disease is seen in the normal population with a frequency of 0.4% 29 but is probably underreported and it can be argued that only subjects developing extreme forms of penile deviation seek medical help. Indeed, in the majority of our own subjects, penile curvature develops as a result of plaque development on the dorsal side of the penis, which is not in the vicinity of the injection sites. This development of penile curvature after IC treatment is age-dependent and in some cases, is suf®cient for some men to abandon this form of erection therapy.
IC treatment is usually used by men with normal libido, since it is this motivation to experience intercourse which causes the vast majority to seek medical help for their impotence. Never the less, in those generally satis®ed with the treatment, 82% reported that their sexual desire was at least partly enhanced after embarking on IC medication, 60% convincingly so. It is understandable that many impotent men will suffer from a degree of inhibited sexual desire as a defence reaction to their erection problems. The increase in con®dence resulting from the successful application of IC treatment would be expected to increase their libido and a greater willingness to initiate sexual contact. Gheorghiu 30 registered over a doubling in the frequency of intercourse in his subjects embarking on a programme of IC treatment. The resulting increase in self esteem also at least partly explains why 80% of those satis®ed with the technique admitted a subsequent improvement in the quality of their lives. This con®rms the results of several previous studies. 30 ± 32 Slightly over half of the subjects admitted to experiencing some spontaneous erections before starting IC treatment. In less than a ®fth, did IC treatment improve the quality of these erections. Similarly, the treatment did not to a major extent reduce the subjects dependency on IC medication with time, nor did it encourage a reduction in the dose necessary to achieve an adequate erection. Basile 33 registered a reduction in dose necessary to achieve rigidity in only 17%, which is comparable to this present study. Furthermore, in Basile's study only 16% reported a decreased need for selfinjection. These observations are in accordance with the majority of studies (see reference 34) who report a relative low incidence of spontaneous complete recovery after IC treatment, 5 ± 10% depending on the report. On the other hand, at least one author has reported that the combination of cognitive and behavioural therapy and IC treatment can result in a spontaneous recovery rate as high as 57% with the alpha antagonist Moxisylyte and 14.3% with prostaglandin E1 and 21.2% with papaverine. 35 This implies that in many cases, continued dependence on the treatment does not re¯ect irreversible organic changes in the cavernosal tissue but a deep seated performance anxiety or other untreated psychological con¯icts. These results need to be con®rmed by other groups since it is in con¯ict with many of the current theories on the etiology of impotence.
The proportion of men ceasing to use IC therapy after initially electing to use this form of treatment for their erectile failure was approximately 40%, the majority after at least six months use. This number is relatively low compared to some published drop-out rates, which can reach 80%. The ®rst follow-up studies had already indicated a drop-out rate from cavernosal injection programme of 40 ± 50%. 36, 37 Later studies indicated rates of 76% at 6 months follow-up with PGE, 38 80% at 11 months with papaverineaRegitine, 39 52% at 10 months with TRIMIX 40 and 42% at 3.9 y 41 and 68% at 5 y with papaverineaphentolamine 6 . Why drop-out rates differ so markedly between the different studies is unknown. It may re¯ect the degree of physician involvement regarding the extent of testing to ®nd the appropriate dose and type of medication, the use of injection aids or the degree of training and followup. The age of the subject, the mode of injection or the type of medication did not appear to explain a reluctance to use IC therapy.
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As could be anticipated, over 80% continuing to use IC treatment were either satis®ed or partly satis®ed with the technique. More interesting was the ®nding that despite dropping out from the programme, 52% had been satis®ed or partly satis®ed with IC therapy suggesting that in many cases, factors other than those related to the technique were responsible for their decision. In general, those expressing dissatisfaction with the technique were more often in the younger age groups, which may re¯ect disappointment with an increasing dependency on this form of treatment. This would be more expected in in¯uence self esteem in the younger men than older subjects who tend to be more resigned to dependency because of organic etiology. It may also re¯ect the observation that painadiscomfort associated with PGE injection was more often experienced with younger subjects (Table 6) .
When asked to register the reasons for dissatisfaction or drop out from IC treatment, the most common reason was inadequate penile rigidity. All of these subjects had been tested with medications by the physician until an adequate penile response had been obtained prior to self injection. This suggests that either they had overestimated the degree andaor duration of rigidity necessary for intercourse during the testing phase, that the stress of self injection combined with performance anxiety were suf®cient to inhibit the response or that the underlying organic cause of their erection failure had been further exacerbated. In such cases, use of higher concentrations or more potent preparations such as TRIMIX may have provided a better response. This lack of response to the IC treatment was age-dependent which may re¯ect a combination of a lower motivation in higher age groups to renew contact with the physician or a lack of awareness that more potent drug formulations. The expense of the medication was also of major importance, a consideration which could not be related to the age of the subject. In Norway, it is only relatively recently that the high costs of PGE medication could be partly reimbursed by the medical welfare. Hence this reason for stopping IC treatment is at the present time less justi®able, although this is of course dependent on the frequency of intercourse. It does however indicate that the cost of treatment is an important consideration for patients faced with different treatment modalities for their erection failure. Pain or discomfort after PGE injection has been recorded in several studies. 4, 42, 43 In this present study, this was the third most important source of dissatisfaction, but more often in the younger age groups. This problem could have been solved by simply switching the subjects over to papaverineaphentolamine which is acknowledged not to cause this type of discomfort.
A fourth criticism which is more dif®cult to reconcile is that IC treatment is lacking in spontaneity. This was considered even more of a problem for the partner who ranked this as second in importance in the list of reasons for her dissatisfaction with the technique. Regardless of the form of erection treatment, some degree of spontaneity must unfortunately always be sacri®ced. Indeed compared to new modalities such as oral treatment 44 which has to be taken 1 h before intended intercourse, IC injection is relatively more spontaneous, involving treatment only 10 ± 20 min before intercourse. In the dissatis®ed group, in some cases both partners regarded the procedure as being too complicated, a criticism which will cause many to favour changing over to oral preparations in the future, in spite of this lack of spontaneity.
Certain men expressed dissatisfaction because they felt that IC therapy was responsible for alterations in the shape of the penis, more usually an abnormal bending of the shaft. This was far more often associated with the older subjects and may re¯ect the development of Peyronie in certain susceptible individuals. As discussed previously, this could not be related to the medication or the mode of injection employed. In a relative small number of cases, the return of spontaneous erections was registered as a reason for discontinuing IC treatment. This occurred almost four times more often in the 25 ± 40 y than the 71 ± 93 y age group, presumably re¯ecting the greater importance of psychological factors in the younger men. The rate of spontaneous recovery reported by the various studies is variable but generally between 5 and 10% of those using self injection. 33, 45 This ®gure would be expected to re¯ect the general age of the study group, the proportion of those with psychogenic impotence but also the degree to which IC treatment is combined with psychotherapy. 35 The advent of new, effective oral medications for erectile failure such as sildena®l, 44, 46, 47 means that intracavernosal treatment will inevitably be relegated to a secondary treatment modality. However as indicated by the present study, the price of treatment is a major consideration for many patients and sildena®l is relatively expensive. Although the side effects of sildena®l are few and of low incidence, 48 over the long term, the visual disturbances, headache, heartburn and nasal congestion may persuade a signi®cant number of subjects to alternate with different treatment modalities. More signi®cantly, the major contraindication for sildena®l is the use of nitrate preparations in the treatment of angina (Data on ®le, P®zer Inc.) which involves a relatively large proportion of the elderly population. Indeed, reports of sudden death after sildena®l treatment have deterred a number of relatively healthy, elderly subjects from trying the preparation, a decision often encouraged by their spouses (personal observations). In addition, the apparent bene®cial effects of intracavernosal medication on ejaculatory control may also be a decisive factor in treatment choice for certain subjects.
Conclusion
IC therapy can, if used correctly by an appropriate group of men with erectile failure, stimulate libido, increase ejaculatory control and improve the quality of life. However, the technique is seldom 100% effective, a large number of men remain dependent on it and in some cases it may activate Peyronie-like changes in the penis. The rate of continuance of IC therapy after sixth months is relatively high in spite of various drawbacks with the technique. In the majority of those expressing dissatisfaction with the technique, the causes of their dissatisfaction are potentially avoidable including inadequate penile rigidity (close follow-up by the physician, testing of drugs with higher potencies), high drug costs (seek reimbursement from medical welfare), penile painadiscomfort after injection (replace PGE by papaverineaphentolamine) or too complicated procedureaneedle phobia (emphasis on injector aids). Other reasons related to the lack of spontaneity of the technique, a lack of sexual desire in the subject andaor partner or deterioration in the health of the couple are problems which are more dif®cult to circumvent and will discourage many couples from embarking on any form or erection treatment.
